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Abstract 
Background: Non alcoholic fatty liver disease (NAFLD) is abnormalities of 
metabolism resulting in fat deposition in the hepatocyte occurred in people who do 
not consume alcohol. Carbohydrate and fat intake, also visceral fat deposition has 
been studied as a risk factor of NAFLD, however the results remain elusive.  
Objective : To identity the nutritional and clin ical risk factors of the incidence and 
severity of NAFLD.  
Methods: This study was done from June to December 2014 in the Dr. Kariadi 
Hospital Semarang. A case-control group was established comprising 33 patients 
with NAFLD based on the ultrasonography (USG) criteria (case group) and 34 
healthy subject (control group). Carbohydrate and fat intake was assessed by using 
the food frequency questionnaire (FFQ), visceral fat deposition was measured by 
body impedance analysis (BIA), and clinical markers were obtained from 
laboratory data. 
Results: Carbohydrate intake, fat intake, and visceral fat deposition were risk 
factors of the incidence and severity of NAFLD (OR=7.8, CI95% 2.43-25.45;  
OR=5.9, CI95% 2.0-17.57; OR=50.7, CI95% 6.16-418.09) and (OR=0.9, CI95%  
1.06-90.58; OR=14.6, CI95% 1.37-156.88; OR=6.6, CI95% 1.17-37.78). 
Multivariate regression showed that the most important risk factor of NAFLD for 
the incidence and severity were hypertriglyceridemia (OR=8.7, CI95% 2.20-34.44) 
and fat intake (OR=48.4, CI95% 2.78-844.1), respectively. 
Conclusion: High carbohydrate intake, fat intake, and high visceral fat deposition 
are risk factors of the incidence and severity of NAFLD. Hypertrig lyceridemia and 
fat intake are the most important risk factor of NAFLD incidence and severity, 
respectively. 
 
Keywords :  Non alcoholic fatty liver disease, carbohydrate intake, fat intake, 
visceral fat, risk factor 
INTRODUCTION 
 Non Alcoholic Fatty Liver Disease (NAFLD) is a  
liver disorder that is histologically similar to  
Alcoholic Fatty Liver Disease (ALD), but occurs in 
patients who do not consume alcohol.  
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 This disease is caused by abnormalities of 
metabolism resulting in fat deposition in the 
hepatocyte.
1,2
 NAFLD spectrum is very broad, 
ranging from simple fatty liver, fatty liver d isease 
with NAFLD, Liver Cirrhosis and Hepatocellular 
Carcinoma.
3
  Approximately 37% of ALD patients on 
the simple fatty liver spectrum will develop into Fatty 
Liver Disease with NAFLD, 45% develop into 
cirrhosis within 7 years, and then 5-8% develop into 
hepatocellular carcinoma within 1 year.
4
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 In the last decade, the prevalence of NAFLD 
around the world has increased rapidly. World  
Gastroenterology Organization mentioned that 
NAFLD is the number one liver disease in western 
countries. An estimated 6 million Americans 
experience NAFLD. NAFLD incidence in some 
countries in Asia is reported to be about 5-40% 
depending on the population studied. NAFLD 
prevalence in the general population in Japan in 1988 
was about 9-14% and there has been a significant 
increase in obese populations in the last two decades. 
NAFLD in India is estimated at 5-28%, and in China 
with liver ultrasound (ultrasound) examination, 
NAFLD prevalence is approximately 15%.
5  
 Specific research on NAFLD has not been done in 
Indonesia. Several studies of NAFLD suggested that 
30.6% NAFLD prevalence and important risk factors 
reported were metabolic syndrome, obesity, type 2 
diabetes mellitus, insulin resistance (IR), and  
hypertriglyceridemia where caused by high food 
intake of carbohydrate and high fat intake is closely 
related to these risk factors.
6,7
  
 The objective of this study was to identity the 
nutritional and clinical risk factors of the incidence 
and severity of NAFLD. 
 
MATERIALS AND METHODS  
 This study was a case-control study.
47
 The scope 
of this research was in the field of Clin ical Nutrition  
Sciences and Internal Medicine Sub Section  
Gastroenterohepatology that conducted in Internal 
medicine clinic sub Gastroenterohepatology Dr. 
Kariadi Semarang Hospital between June and 
December 2014. 
Study Subjects 
 The target population were patients in the 
Gastroenterohepatology clinic of Dr. Kariadi Hospital 
Semarang, with the reasonably affordable population 
for the case was patients who had been diagnosed 
with NAFLD, who had been screened early on and 
there was no change of diet and physical activity in  
the last 5 years. An population for control was a 
person who on an ultrasound examination that 
performed by a Gastroenterohepatology consultant, 
was not found NAFLD or other liver disease, and 
there was no history of taking medications that cause 
liver disorders.  
 Inclusion criteria of case subject were patients 
with: (a)Viewed from NAFLD diagnosed medical 
record, (b) Positive abdominal ultrasound for NAFLD 
(c) Not taking any medicines or herbs that interfere  
with the liver function or that cause fatty liver and (d) 
Not taking any medicines or herbs that inhibit fat 
absorption, fat burners, and weight loss (e) Not 
suffering from liver disease other than NAFLD (f) 
Passes screening on diet and living habits (see 
appendix) (g) Willing to be subject of the study. 
Exclusion criteria were having abnormalit ies and/or 
congenital defects that can interfere with research 
measurements. Inclusion criteria of control subject 
were patients (a) without history and symptoms of 
liver disease (b) who had not any liver abnormalit ies 
on ultrasound examination. Exclusion criteria  in the 
control group were the same as the case group. 
 
Data processing 
 Data collection is done manually using the 
research form provided. Food intake assessment was 
done with semiquantitative FFQ, which then 
conducted data entry using intake analysis program 
with Nutrisurvey Program. Physical Activity  
Assessment based on interviews using International 
Physical Activity Questionnaire (IPAQ) was then 
calculated with an automatic calculator IPAQ score 
instrument. 
 
Data analysis 
 Univariate analysis of variables analyzed data 
normality then data is presented in the form of 
distribution table and description. Bivariate analysis 
is an analysis to determine the relationship of each 
risk factor with NAFLD using test in accordance with 
the variables analyzed. Data from the variables 
corresponding to the p value <0.25 were included in a 
multivariate log istic regression analysis. 
 The study was approved by the University-
Hospital's Ethics Committee (no. 128/EC/FK-
RSDK/2014) and all patients provided written 
informed concept before participation. 
 
RES ULTS  
Overview of Research Subject 
 NAFLD group obtained 33 subjects in which 15 
men and 18 women, while healthy controls were 34 
subjects with 12 males and 22 females. There were no  
difference of characteristics of subjects in this study 
in general. The age range was 28-68 years and the 
mean age was 43.39 years. While the control group 
obtained 34 subjects, with female gender more than 
men. Age range 28-55 years and average age 40.76 
years. The mean of Waist circumference in the 
NAFLD group was higher than the control. Based on 
Waist circumference and sex by Asian classification, 
NAFLD subjects had more central obesity than those 
who did not, while control subjects who had fewer 
central obesity than those who did not. The mean of 
BMI in the NAFLD group was higher than the 
control, there was even a NAFLD subject with 43 kg /  
m2 IMT (Table 1).  
 Most of the subjects from both groups are civil 
servants and all research subjects in both groups have 
middle to upper economic level where their income is  
above min imum wages rate for Semarang in 2014. 
Subjects in both groups have more activity than those 
with low activ ity. None of the subjects of the two 
groups had high activity. The NAFLD group in this 
study had a diverse NAFLD Fibrosis Score, but after 
classification according to its degree, the number of 
subjects was almost the same between groups. A total 
of 10 (30.3%) NAFLD subjects had a low NAFLD 
Fibrosis Score, 11 (33.3%) of NAFLD subjects had 
moderate Fibrosis Score NAFLD, and 12 (36.4%) 
NAFLD subjects had high NAFLD Fibrosis Score 
(Table 1). 
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Table 1. Baseline patients' characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbohydrate and Fat intake, as well as Visceral 
Fat Deposition Score  
 Carbohydrate and fat intake in NAFLD group was 
higher than control. The mean visceral fat deposition 
based on BIA scores in the NAFLD group was higher 
than in the control (Table 2). 
 
Table 2. Description of Carbohydrate, Fat intake and 
Visceral Fat Deposition Score of Research subject 
 
No Variabel NAFLD 
Mean ± SB 
(Min-Max) 
Control 
Mean ± SB 
(Min-Max) 
1 Carbohydrate 
Intake (gram) 
315.8±128.4 
(125.9-602.2) 
216.2±65.2 
(107.4-
391.7) 
2 Fat Intake 
(gram) 
74.6 ±36.5 
(17.8-204.5) 
54.8±22.7 
(17.9-115.4) 
3 Visceral Fat 
Deposition Score 
12.6 ±6.5 
(4.0-30.0) 
5.5  ±3.3 
(1.0-12.0) 
Risk Factors of NAFLD Incidents 
In determin ing the risk factors for NAFLD 
events, the determination of the classification of 
carbohydrate and fat intake,  
as well as visceral fat classification was based on the 
results of Receiver Operating Characteristic (ROC) 
against Recommended Daily Allowance (RDA) 
analysis (Figures 1) 
 
 
 
 
 
 
Figure 1. (a) Carbohydrate Intake against RDA. (b) 
Fat Intake against RDA. (c) Visceral Fat Deposition, 
on Case-Control Group. 
 
 In bivariate analysis towards nutritional variab les 
such as: high carbohydrate intake, high fat intake, and 
high deposition of visceral fat, were shown to be the 
risk factor for NAFLD incidence (Table 3). Clinical 
markers such as visceral obesity, insulin resistance, 
dyslipidemia,  hyper trigliseridemia, Hipo-HDL, 
hypertension, and metabolic syndrome were also 
proved to be the risk factor for NAFLD incidence.  
 Multivariate analysis was performed on risk 
factors of NAFLD incidence, indicating that 
hypertriglyceridemia was the most influential factor 
(OR 8.7, CI95% 2.2-34.4) and visceral fat deposition 
(OR 5.8, CI95% 1.39-24.8) were the independent risk 
factor for incidence of NAFLD (Table 3 and 4). 
 
Table 3. Risk Factors of High Carbohydrate, High 
Fat Intake and Clinical Markers on NAFLD 
Occurrences 
 
 
cut-off point             
fat intake         
against RDA 86% 
cut-off point 
carbohydrate 
intake against 
RDA 79.5% 
Cut off point 
against visceral 
fat= 11.5 
(a) 
(b) 
(c) 
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Table 4. Logistic Regression Test Risk Factors 
Against NAFLD 
 
Carbohydrates and Fats, as well as visceral fat 
deposition According to NAFLD Degrees 
Carbohydrate and fat intake (grams), as well 
as visceral fat deposition (score) increase with  
increasing degree of NAFLD (Figure 2). 
 
 
 
 
 
 
 
 
Figure 2. Correlation Between (a) Carbohydrate, (b) 
Fat Intake, and (c) Visceral Fat Deposition with  
NAFLD Degrees  
 
Risk Factors of NAFLD Severity 
 The severity of NAFLD from the in this study is 
divided into 3 groups, but on the risk factor analysis 
for NAFLD severity we classify them into 2 groups, 
where the intermediate and high degree groups we 
make become the severity of the high degree  
NAFLD. While the low degree (low) we use for 
comparison. 
 In determining the severity risk factor of NAFLD, 
the determination of the classificat ion of carbohydrate 
and fat intake, as well as fat classification is based on 
the results of Receiver Operating Characteristic  
(ROC) analysis (Figure 3). 
 
No Variables B SE Sig OR CI95% 
1. Hipertrigliseri
demia 
2.16 0.70 0.002 8.7 2.20-34.44 
2. Visceral Fat 
Deposition 
1.77 0.73 0.016 5.8 1.39-24.82 
(a) 
(b) 
(c) 
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Figure 3. (a) Carbohydrate Intake against RDA. (b) 
Fat Intake against RDA. (c) Visceral Fat Deposition, 
on Case Group 
 
 Based on bivariate analysis showed high 
carbohydrate (>90% RDA) and fat intake (>47,5% 
RDA), visceral fat deposition score >7,5% were 
proved as risk fators of NASH or severity of NAFLD 
(table 5). 
 However, in mult ivariate analysis, only high fat 
intake (>47,5%) proved as a risk factor for NAFLD 
severity or incidence of NASH (p= 0.008). 
 
Table 5. Risk Factors Carbohydrate and Fat intake, 
Visceral Fat Deposition Score Against the severity of 
NAFLD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 On bivariate analysis for clinical markers on 
NAFLD severity showed that visceral obesity and 
metabolic syndrome were as risk factors for NAFLD 
severity consecutively (OR 7.1 (1.35-37.55) and OR 
6.6 (1.17-37.7)) (table  6). 
 
Tabel 6. Risk Factor of Clin ical Markers on NAFLD 
Severity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSS ION  
 The result of statistical test of the characteristics 
between two groups (age, sex, occupation, income, 
and physical activity) showed no difference, this  
indicated the initial condition in both groups is alike 
except in the variable of central obesity, insulin 
resistance, dyslipidemia , hypertriglyceridemia, hypo-
HDL, hypertension, and metabolic syndrome. 
 The mean of age on the NAFLD group was 43.3 
years, while the control was 40.8 years. Age is one of 
cut-off point 
carbohydrate  
against RDA 
=90% 
cut-off point fat 
against RDA 
=47.5% 
Cut off point 
against visceral 
fat    =7.5 
(a) 
(b) 
(c) 
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the predisposing factors for NAFLD. The aging  
process will increase the oxidative stress that plays a 
role in the process of NAFLD 
 Insulin resistance is a risk factor for the incidence 
of NAFLD (OR 3.3, CI95% 1.01-10.83). It may cause 
metabolic disorders of some macro nutrients due to 
hepatic insulin resistance resulting in increased 
plasma glucose concentration and increased VLDL 
production and cause hypertriglyceridemia. 
Trig lycerides will accumulate in the hepatocyte so 
that NAFLD will occur. Th is result is consistent with 
Cortez et al's 2006 study which suggests that there is 
a significant difference (p <0.01) between NAFLD 
patients in the Fatty Liver Disease with NAFLD 
spectrum compared with healthy control.
48
 Studies by 
Hannah et al, 2014 suggest that there was a 
significant difference (p <0.05) between NAFLD 
patients on simple steatosis spectrum and NAFLD 
compared with healthy control.
49
 This result is 
directly proportional to Lei et al's 2012 study, which 
states that RI is one of the risk factors for NAFLD 
with 4.96 times compared  with healthy control (95% 
CI 1.10-22.266 ).
50
 
 Each of the metabolic syndrome components such 
as central obesity, dyslipidemia, h ipertrig liseridemia, 
hipo-HDL, insulin resistance and hypertension as 
well as stand-alone variables as the variables studied 
are risk factors for NAFLD events. Metabolic  
syndrome is the risk factor for the incidence (OR 
23.4, CI95% 6.30-87.06) and severity of NAFLD 
(OR 6.6, CI95% 1.17-37.7), as well as central obesity 
(CI95% 1.35-37.55). 
 Multivariate analysis showed that 
hypertriglyceridemia and fat intake were independent 
risk factor for NAFLD incidence. These results fit the 
theoretical basis that dyslipidemia, in particular 
hypertriglyceridemia, can result from a h igh fat intake 
and may increase the risk of incidence and severity of 
NAFLD.
31,32
 The results of this study are consistent 
with Lei et al's 2012 study of multivariate tests 
suggesting that dyslipidemia increased the risk of 
incidence of NAFLD 4.405 times compared with  
healthy control (p = 0.004) .
50
 Similarly, Hannah et 
al's study, 2014, stated that there was a significant 
difference in the presence of dyslipidemia (p = 0.05) 
between NAFLD patients with healthy control.
49
 
There was a 4-11 times individual risk with metabolic  
syndrome to suffer NAFLD than healthy 
individuals.
33
 
 Descriptive analysis (box p lot) showed that 
average carbohydrate intake in NAFLD group was 
higher than control. Average fat intake in NAFLD 
group was also higher than control. The results were 
consistent with Cortez's 2012 study suggesting that 
fat and carbohydrate intake in NAFLD patients was 
higher than in controls and significantly different.
48
 
The Israeli study by Sagi et al, 2007 showed different  
results, whereas fat intake in NAFLD and healthy 
control, showed no difference (p = 0.76) similar with  
carbohydrate intake also no difference (p = 0.6). 
Although the intake of both groups was not 
significantly different, the multivariate analysis 
showed that carbohydrate intake (from soft drinks) 
was a risk factor for NAFLD (OR 1.45, CI95% 1.13-
1.85) .
7 
After classificat ion based on ROC curve cut-
off, intake of carbohydrate and fat to RDA according 
to individuals, showed  a relationship of fat and 
carbohydrate intake with the incidence and severity of 
NAFLD. Intervariable test showed that high 
carbohydrate and fat intake increased risk of NAFLD 
incidence (OR = 7.8, 95% CI 2.43-25.45), (OR = 5.9, 
CI95% 2.00-17.57). High carbohydrate and fat 
intakes increase the risk of NAFLD severity (OR = 
9.8, 95% CI 1.06-90.58), (OR = 14.6, CI95% 1.37-
156.88). 
 Increased intake of carbohydrate and fat is closely 
related to elevated blood glucose, FFA, insulin  
concentration. A person with a higher fat intake 
(>37%), would increase the risk of NAFLD by 2.51 
times compared with healthy control.
51
 High fat 
intake along with IR through LpL and the genetic 
changes of the fat metabolism pathway will increase 
the blood FFA so that the concentration of TG and 
CE in the liver and fat in the muscle increases and 
accumulates. Excessive carbohydrate intake 
combined with IR will also increase the stimulation  
of de novo lipogenesis so that glucose in the liver 
increases. Glucose will be converted to glycogen and 
FFA. Glycogen will increase FC and increase CE, 
whereas FFA will increase TG and CE and eventually 
lead to excessive accumulation of TG in the liver and 
infiltrate hepatocytes and then form NAFLD.
12 
FFA  
also increase DAG (d iacylglyserol). Accumulation of 
DAG interferes with insulin signaling in the liver by 
activation of protein kinase-C. Ceramide on the 
spingolipid membrane will also increase FFA in the 
liver and contribute to insulin resistance through 
activation of proinflammatory cytokines, cell 
apoptosis and increased endoplasmic reticu lum 
stress.
52
 
 High visceral fat deposition is a risk factor for the 
incidence and severity of NAFLD (OR 50.7, 95% CI 
6.16-418.09), (OR 6.6, 95% CI 1.17-37.78). The 
visceral fat deposition in a person with obesity and 
overweight will increase adipose tissue, where 
adipose tissue is the site of macrophage accumulation  
which is the main source of TNF-α expression. TNF-
α secretion then stimulates MCP-1 by preadipocytes. 
TNF-α, interleukin-6, interleukin -1β are secreted by 
activated macrophages.
12
 These proinflammatory  
cytokines will lead to stem cell act ivation and cause 
fibrosis, in addition the kupfer cells will also be 
activated to produce proteins acute phase such as 
CRP and protrombosis molecules all of which will 
result in liver tissue damage (Hit 2) 
.12
 Increased 
visceral fat deposition boosting proinflammatory  
cytokines will also increase ROS, affect lipid  
peroxidation and decrease adiponectin. Adiponectin is 
an anti-inflammatory adipocytokine that modulates 
the effects of insulin. Adiponectin levels are 
negatively correlated with fasting sugar levels, and 
insulin resistance and TG levels. Decreased 
adiponectin will promote more intensive 
necroinflammation in NAFLD. High necro-
inflammat ion will increase ROS and lead to increased 
peroxidation of fu rther pro-inflammatory lipid and  
43 
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cytokine products leading to cell death, inflammation, 
and fibrosis.
53
 
 The result of multivariate test stated that 
hypertriglyceridemia was the independent risk factor 
for the incidence of NAFLD. Hypertriglyceride is the 
beginning of triglyceride buildup in the liver which  
will damage the structure and function of the liver so 
that it develops into various diseases like IR, DM, 
dyslipidemia, and metabolic syndrome which is a 
pathogenesis that can not be separated with NAFLD 
disease. Nevertheless, the above risk factors after the 
regression test contributed 55.3%, and as much as 
44.7% may be influenced by other factors not 
investigated but related to NAFLD.  
 The overall risk factors above must be addressed 
comprehensively. Handling either medically or non-
medically as nutrition therapy as indicated or with  
lifestyle changes, and good dietary regulation, and 
education to the patient as a follow-up to prevent 
NAFLD should be done. 
The limitations of this study are: data was 
taken from a single measurement, so that can not 
always describe a relationship in the longer time. FFQ 
method, has weakness, including recall b ias, and 
underestimate or even overestimate the size of 
household food subject intake. FFQ can not provide 
informat ion about the intake of simple carbohydrates, 
fructose, or certain antioxidant intake that may be 
related to the process of NAFLD. 
 
CONCLUS ION  
 High carbohydrate intake, fat intake, and high 
visceral fat deposition are risk factors of the incidence 
and severity of NAFLD. Hypertriglyceridemia and fat 
intake are the most important risk factor of NAFLD 
incidence and severity, respectively.  
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